Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study
Alimentary Pharmacology & Therapeutics · 2026-08 · 64 (3) · 326-333
DOI: 10.1111/apt.70695 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 20.04.2026. Verfasst von Adriana Palom und 17 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit, Hospital Univesitari Vall d'Hebron, Barcelona, Spain. Hauptthemen laut MEDLINE: Liver Cirrhosis, RNA, Viral, Hepatitis Delta Virus, Hepatitis D, Chronic. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Instituto de Salud Carlos III.
Abstract (Originalsprache)
Background and Aims Chronic hepatitis D (CHD) is associated with rapid progression to liver cirrhosis. However, the prognostic relevance of quantitative serum HDV‐RNA remains incompletely defined. We aimed to evaluate whether baseline HDV‐RNA levels are associated with the risk of liver‐related events in untreated patients with CHD and to validate these findings in two independent European cohorts.
Methods
We conducted a multicentre retrospective‐prospective cohort study including 260 untreated adults with CHD and detectable HDV‐RNA. Patients were derived from a Spanish derivation cohort ( n = 98) and two Italian validation cohorts ( n = 100 and n = 62). Baseline serum qHDV‐RNA was categorized in 1‐log increments starting from 6 IU/mL.
Results
During a median follow‐up of 4.1 years, 74 patients (28%) experienced at least one liver‐related event, with a significantly higher incidence in patients with cirrhosis than in those without cirrhosis ( p < 0.001). Among noncirrhotic patients, increasing baseline HDV‐RNA levels were consistently associated with a higher proportion of liver‐related events across derivation and validation cohorts, whereas no events occurred at the lowest HDV‐RNA category. In contrast, among patients with established cirrhosis, baseline HDV‐RNA levels were not associated with the occurrence of liver‐related events, and cumulative incidence was comparable across viral load categories.
Conclusions
Baseline quantitative HDV‐RNA allows early risk stratification in untreated patients with chronic hepatitis D before the development of liver cirrhosis. Once cirrhosis is established, clinical outcomes are largely independent of viral replication, emphasising the need to prioritise timely antiviral intervention and close surveillance at earlier disease stages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Unit, Hospital Univesitari Vall d'Hebron, Barcelona, Spain.
- CIBERehd, Madrid, Spain.
- Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Hepatology Unit, University Hospital, Pisa, Italy.
- Gastroenterology Hepatology and Transplantation Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
- Citta della Salute e della Scienza di Torino (City of Health and Science of Turin), School of Medicine, Department of Medical Sciences, University of Turin Department of Medical Sciences, University of Turin, Turin, Ita…
ORCID-Profile: Elisabetta Degasperi, Alessandro Loglio, Angela Carvalho-Gomes, Loretta A Kondili, Mauro Viganò, Pietro Lampertico
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
Palom, A., Degasperi, E., Coco, B., Loglio, A., Ciancio, A., Niro, G. A., Riveiro-Barciela, M., Carvalho-Gomes, A., García-Samaniego, J., Lens, S., Rando-Segura, A., Sambarino, D., Cotugno, R., Kondili, L. A., Brunetto, M., Viganò, M., Lampertico, P., & Buti, M. (2026). Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study. Alimentary Pharmacology & Therapeutics, 64(3), 326-333. https://doi.org/10.1111/apt.70695
Vancouver
Palom A, Degasperi E, Coco B, Loglio A, Ciancio A, Niro GA, et al. Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study. Alimentary Pharmacology & Therapeutics. 2026;64(3):326-333. doi:10.1111/apt.70695
BibTeX
@article{Palom2026,
author = {Palom, Adriana and Degasperi, Elisabetta and Coco, Barbara and Loglio, Alessandro and Ciancio, Alessia and Niro, Grazia Anna and Riveiro-Barciela, Mar and Carvalho-Gomes, Angela and García-Samaniego, Javier and Lens, Sabela and Rando-Segura, Ariadna and Sambarino, Dana and Cotugno, Rosa and Kondili, Loretta A and Brunetto, Maurizia and Viganò, Mauro and Lampertico, Pietro and Buti, Maria},
title = {Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {64},
number = {3},
pages = {326--333},
doi = {10.1111/apt.70695}
}
EUVIMED